Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice

Julia E. Rood, Sheila Rao, Michele Paessler, Portia A. Kreiger, Niansheng Chu, Erietta Stelekati, E. John Wherry, Edward M. Behrens

Blood (2016) 127 (4): 426–435.

https://doi.org/10.1182/blood-2015-07-659813

Published: 2016

Includes: Supplemental data

Journal Articles

Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).

Elena Cherkasova, Elizabeth Malinzak, Sheila Rao, Vera N. Senchenko, Anna V. Kudryavtseva, Lev L. Kiselev, Yoshiyuki Takahashi, MD, PhD, Nanae Harashima, W. Marston Linehan, M.D, Ramaprasad Srinivasan, MD, PhD, Michael I. Lerman, Richard W. Childs, MD

Blood (2009) 114 (22): 467.

https://doi.org/10.1182/blood.V114.22.467.467

Published: 2009

Journal Articles

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Aleah Smith, BS, Maria Berg, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1786.

https://doi.org/10.1182/blood.V110.11.1786.1786

Published: 2007

Journal Articles

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Andreas Lundqvist, PhD, Sheila Rao, BS, Maria Berg, BS, Aleah Smith, BS, Su Su, PhD, Hisayuki Yokoyama, PhD, Shivani Srivastava, MD, Richard Childs, MD

Blood (2007) 110 (11): 1789.

https://doi.org/10.1182/blood.V110.11.1789.1789

Published: 2007

Journal Articles

Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100.

Aleah L. Smith, BS Biology, Joo Jungnam, PhD, Sheila Rao, BA Molecular Biology, Andreas Lundqvist, PhD, Lisa W. Cook, BSN, Rose S. Goodwin, BSN, MS, Catalina Ramos, BSN, Nancy L. Geller, PhD, Richard W. Childs, MD

Blood (2007) 110 (11): 3277.

https://doi.org/10.1182/blood.V110.11.3277.3277

Published: 2007

Journal Articles

A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

Steven J. Lemery, MD, Matthew M. Hsieh, MD, Aleah Smith, Sheila Rao, Hanh M. Khuu, Donohue Theresa, PA, Jennifer M. Karpovich, NP, Lisa Cook, RN, Rose Goodwin, RN, Carol Boss, MPH, Gary Calandra, Nancy Geller, PhD, John Tisdale, MD, Richard Childs, MD

Blood (2007) 110 (11): 3278.

https://doi.org/10.1182/blood.V110.11.3278.3278

Published: 2007

NARROW

ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice

Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100.

A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

Email alerts

ASH Publications

American Society of Hematology

ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice

Loss of Function of the VHL Tumor Suppressor Gene Resurrects An Endogenous Retrovirus in Kidney Cancer That Encodes a Tumor Antigen Targeted by Allogeneic T-Cells Following Hematopoietic Cell Transplantation (HCT).

Bortezomib Enhances the Antitumor Activity of Adoptively Infused Natural Killer Cells In Vivo: A Novel Approach To Override KIR-Mediated Inhibition of NK Cell Cytotoxicity.

The Proteasome Inhibitor Bortezomib Simultaneously Enhances NK Cell Tumor Cytotoxicity While Paradoxically Reducing Antigen Specific T-Cell Tumor Cytotoxicity.

Significant Alterations in T-Cell TH1 and TH2 Cytokine Gene Profiles Associated with G-CSF Mobilization Do Not Occur in T-Cells Mobilized with AMD3100.

A Pilot Study Evaluating the CD34+ Cell Mobilizing Activity and Adverse Events Associated with Escalating Doses of AMD3100 in Healthy Volunteers.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only